CD33 and myelodysplastic syndrome: BI 836858, another CD33 monoclonal antibody glycoengineered against CD33 has also not shown much promise in untreated patients with MDS/AML, with only 18% patients achieving a CR/CRi among 28 patients with untreated AML in the phase I/II dose-escalation study of BI 836858 in combination with azacitidine (AZA) as part of the Beat AML dataset [65].